New Physiologically Active Kaempferol Glucoside from Abutilon pannosum.

Abdullah I. Kamel Chemistry Department Faculty of Science Mansoura University Mansoura, Egypt Manal G. Elfedawy Chemistry Department Faculty of Science Mansoura University Mansoura, Egypt

Mamdouh Abdel-Mogib Chem. Dept., Fac. of Sci., Mansoura University Mansoura, Egypt Maha M.ElShamy Botany Department Faculty of Science Mansoura University Mansoura, Egypt |

Abstract:

The phytochemical investigation of *Abutilon pannosum* (Malvaceae) collected from arable land of Tennidah village, Dakhla Oasis, Western Desert, Egypt, resulted in the separation and identification of a new flavonoid, kaempferol 4'-O-(6"-O-E-*p*-coumaroyl)- β -D-glucopyranoside **1** from butanol fraction, in addition to the identification of the volatile constituents of petroleum ether and methylene chloride by GC/MS analysis. Structure of the separated compound was elucidated by spectral analysis. Additionally, the antimicrobial, antioxidant activities and cytotoxicity of different fractions of *Abutilon pannosum* and compound **1** were evaluated. The antimicrobial activity indexes of methanol extract (Ap C), compound **1**, methylene chloride extract (Ap B) and petroleum ether extract (Ap A) against *Escherichia coli* were found to be 66.7%, 50.0%, 33.3%, and 0.0%, respectively. While the activity indexes of compound **1**, (Ap B), (Ap C), (Ap A) against *staphylococcus aureus* were 68.2%, 63.6%, 59.1% and 9.1%, respectively, and against *Candida albicans*, their activity indexes were 38.8%, 38.5%, 34.6%, and 11.5%, respectively. The radical scavenging activity of the extracts and standard were found to be in the following order: ascorbic acid (88.6%) > (Ap C) (84.4%) > compound **1** (76.8%) > (Ap B) (59.2%) > (Ap A) (6.3%). The IC50 values against HePG2 indicated that the cytotoxicity of extracts decreased in the order: compound **1** was "very strong", (Ap C) was "strong", (Ap B) was "moderate", and (Ap A) was "weak", while against PC3 of compound **1** was "strong", (Ap B) and Ap C) were "moderate", and (Ap A) was "weak", while against PC3 of compound **1** was "moderate", and (Ap A) was "non-cytotoxic.

Keywords: Malvaceae, *Abutilon pannosum*, flavonoid, kaempferol 4'-O-(6"-O-E-*p*-coumaroyl)-β-D-glucopyranoside, antimicrobial activity, radical scavenging activity, cytotoxicity.

1.1. INTRODUCTION

The Malvaceae, or the mallows, are a family of flowering plants estimated to contain 243 genera with 4225+ species [1]. Well-known members of this family include okra, cotton, and cacao. The genus Abutilon is one of the larger genera of the family Malvaceae [2]. Many authors recorded A. pannosum in Eastern Desert of Egypt [3, 4]. A. pannosum (G.Forst.) Schltdl. was recorded at edges of cultivation and arable lands in some oasis of Southern part of Western Desert [5]. On March 2014, it was collected from, Esbet-Qattara at El-Monira village nearby Pharous Temple, Kharga Oasis (N 25°38'38.64" -E 30°38'38.88") and at Tennidah village (N 25°30'31.08"- E 29°19'57.84") in Dakhla Oasis as a part of Nubian Sothern part of Western Desert, Egypt, along road sides and arable lands. Plantations and other cultivated areas are the preferred habitats of A. pannosum [5]. A. pannosum is a Chaemophyte, Perennial shrubby herb, 1 - 3 m, with erect or spreading stems branch out from the base. The stems are covered with yellow

hairs. The heart-shaped leaves are velvety on both surfaces and have irregularly toothed edges. The flowers are located on the ends of long stalks, and are either solitary or found in clusters. Each flower has five petals which are approximately two centimeters long, and are either yellow or orange with a dark red to purple base. It produces small, rounded fruits which have obvious ridges and furrows. Each fruit is densely packed with flat mericarps. The brown, hairy seeds are usually kidney-shaped. The flowering period is between January and June [6]. A. pannosum is found in tropical Africa, including Djibouti, Eritrea, northern Ethiopia, Egypt and Sudan, and across to West Africa and the Cape Verde Islands. This species also occurs in Asia, where it is found in Saudia Arabia, the United Arab Emirates, Pakistan and India. In Pakistan, it is restricted to Sindh [7].

Preliminary phytochemical screening of *A. pannosum* showed the presence of Alkaloids, cardiac glycosides and steroids **[8]**,

seven known compounds namely, lupeol, beta-sitosterol, stigmasterol, methyl-4-hydroxybenzoate, taraxacin, ursolic acid, and beta-sitosterol-3-O-beta-D-glucopyranoside, have been isolated from the EtOAc soluble fraction of *A. pannosum* [9].

In this article, we present the results of the phytochemical reinvestigation, as well as the antimicrobial, antioxidant and antitumor activities of *Abutilon pannosum*.

2. RESULTS AND DISCUSSION 2.1 Phytochemical evaluation

Separation of butanol extract (Ap D) of Abutilon pannosum afforded a new natural product, kaempferol 4'-O-(6"-O-E-pcoumaroyl)- β -D-glucopyranoside **1**. Additionally, the petroleum ether (Ap A) and methylene chloride (Ap B) fractions were analyzed by GC/MS. A sample from (Ap A) extract afforded 31 compound, with n-nonadecane (8.28%), neicosane (7.63%), n-octadecane (7.31%), n-heptadecane (7.29%), and n-hexadecane (6.54%) being the major components. A sample from (Ap B) extract afforded 29 compound, with phytol (31.69%), squalene (15.76%), neophytadiene (5.58%), and n-hexadecanoic acid (4.97%) being the major components. NMR guided chromatographic separation led to two promising sub-fractions that were analyzed by GC/MS. A petroleum ether sub-fraction (Ap a) afforded 15 compound, with methyl palmitate (38.98%) as a major component, and a methylene chloride sub-fraction (Ap b) afforded 9 compounds with squalene (61.71%) as a major component. Compound 1 was identified by spectral analysis. The ¹H NMR spectrum (Table 1) showed a signal pattern of a kaempferol derivative with H-6, H-8 signals of ring A at δ 6.21, 6.39, in agreement with 5,7-dihydroxy [10, 11], and AA'BB' spin system of ring B with coupling of 8.4 Hz at 8 7.97 and 6.79, indicating the probable 4'-substitution. The spectrum showed also signals of a glucose unit, with the anomeric proton signal at δ 5.46 as a doublet with J of 7.2 Hz, indicating a β -Dglucopyranoside. The signals of H-6 protons shifted downfield at δ 4.05, 4.28 indicating the probable esterification to pcoumaroyl that gave AA'BB' spin system at δ 6.86, 7.38 and the ethylenic H-7, H-8 at δ 6.12, 7.35 as a pair of doublets with trans coupling of 16 Hz. The probable glycosidation at C-3-OH was excluded on the bases of notable shifts of ring B signals [10, 11]. Thus, 1 was identified as kaempferol 4'-O-(6"-O-E-pcoumaroyl)-B-D-glucopyranoside, rather than its isomer cephacoside, isolated previously from the same species [9]. The proposed structure for 1 was confirmed by 1- and 2-D NMR (DEPT, HSQC,HMBC) analysis



2.1. Biological applications

2.1.1. Antimicrobial activity assessment

The antimicrobial activity indexes of methanol extract (Ap C), compound **1**, methylene chloride extract (Ap B) and petroleum ether extract (Ap A) were presented in Table 2 against *Escherichia coli* were found to be 66.7%, 50%, 33.3%, and 0.0%, respectively. While the activity indexes of compound **1**, (Ap B), (Ap C), and (Ap A) against *staphylococcus aureus* were 68.2%, 63.6%, 59.1% and 9.1%, respectively, and against *Candida albicans*, their activity indexes were 38.8%, 38.5%, 34.6%, and 11.5%, respectively (table 2).

2.1.2 Free radical scavenging activity assessment

The anti-oxidant activities of the extracts of *A. pannosum* were presented in Table 3 by (ABTS) method **[12, 13, 14]**. Methanol extract (Ap C) had the highest scavenging activity. The radical scavenging activity of the extracts and standard decreased in the following order: ascorbic acid, methanol (Ap C), compound **1**, methylene chloride (Ap B) and petroleum ether (Ap A) (table 3), respectively.

Table3: ¹H, ¹³C NMR and HMBC data of compound 1

Position	¹ H (multiplicity, J)	¹³ C	DEPT	Long range coupled protons, from HMBC
2		160.44	С	H-2',H-6'
3		133.49	С	
4		177.85	С	
5		156.81	С	
6	6.21, (IH, br.s)	99.23	СН	
7		164.64	С	
8	6.39, (IH, br.s)	94.13	СН	
9		156.90	С	H-8
10		104.31	С	Н-6
1'		125.36	С	H-3',H-5'
2' & 6'	7.97, (2H, d, J= 8.4 HZ)	131.28	СН	
3' & 5'	6.79, (2H, d, J= 8.4 HZ)	116.21	СН	
4'		160.24	С	H-2',H-6', H-3', H-5'
1"	5.46, (1H, d, J= 7.2 HZ)	101.39	СН	
2"	3.37, (IH, m)	74.67	СН	
3"	3.28, (IH, m)	76.65	СН	
4"	3.24, (IH, m)	70.41	СН	
5"	3.21, (IH, m)	74.57	СН	
6"a	4.28, (1H, br.d, J= 12 HZ)	63.40	CH ₂	
6"b	4.05, (1H, dd, J= 12, 5.2 HZ)			
1'''		121.21	С	H-2"',H-6'''
3"" & 5""	6.86, (2H, d, J= 8.4 HZ)	115.54	СН	H-3"',H-5"'
2"" & 6""	7.38, (2H, d, J= 8.4 HZ)	130.61	СН	H-3'",H-5'", H-7"'
4'''		161.59	С	H-2"',H-6"',H-3"',H-5"'
7'''	7.35, (1H, d, J= 16 HZ)	145.06	СН	H-3"',H-5"'
8'''	6.12, (1H, d, J= 16 HZ)	114.07	CH	
9'''		166.63	С	H-7"',H-8"'

Table 2: The inhibition zone in mm of the extracts of Abutilon pannosum and compound 1 compared to standard antibiotics [15]

	E. coli (mg/ml)		S. aureus (mg/ml)		C. Albicans (mg/ml)	
Compound / Fraction	Diameter of inhibition zone (in mm)	% Activity index	Diameter of inhibition zone (in mm)	% Activity index	Diameter of inhibition zone (in mm)	% Activity index
1	12	50	15	68.2	10	38.8
Ap B	8	33.3	14	63.6	10	38.5
Ap C	16	66.7	13	59.1	9	34.6
Ap A	NA		2	9.1	3	11.5
Ampicillin	24	100	22	100	NA	
Colitrimazole	NA		NA		26	100

 $NA \rightarrow No$ Activity.

 Table 3: Antioxidant activity of the extracts of Abutilon pannosum and compound 1 by ABTS

Compound /	Absorbance of	% Inhibition
Fraction	samples	
Control of ABTS	0.520	0%
Ascorbic-acid	0.059	88.6%
Ap C	0.081	84.4%
1	0.120	76.8
Ap B	0.212	59.2%
Ap A	0.487	6.3%

2.2.3 Cytotoxic activity assessment

The IC50 values against HePG2 indicated that the cytotoxicity of extracts decreased in the order: compound 1 was "very strong", (Ap C) was "strong", (Ap B) was "moderate", and (Ap A) was "weak", while against PC3 of compound **1** was "strong", (Ap B and Ap C) were "moderate", and (Ap A) was "weak", and against MCF-7 of compound **1** and (Ap C) were "strong", (Ap B) was "moderate", and (Ap A) was "non-cytotoxic" (table4).

Table 4: Cytotoxic activity assessment of *Abutilon pannosum*extracts and compound 1 against human tumor cells HePG2,MCF-7 and PC3 [16, 17, 18]

• IC50(μ g/ml): 1 – 10 (very strong). 11 – 20 (strong). 21 – 50 (moderate). 51 – 100 (weak) and above 100 (non-cytotoxic).

Compound /	In vitro Cytotoxicity IC50 (µg/ml)•			
Fraction	HePG2	MCF-7	PC3	
5-FU	6.6±0.24	4.7±0.11	9.6±0.27	
1	8.6±0.73	14.0±0.89	19.8±1.13	
Ap C	10.4±0.45	15.3±0.77	23.6±1.06	
Ap B	49.5±2.34	33.6±2.12	22.3±0.98	
Ap A	80.4 ± 4.58	>100	90.7±5.47	

• 5-FU = 5-fluorouracil

3. EXPERIMENTAL

3.1 Instrumentations

$3.1.1^{-1}$ H-NMR

The NMR spectra were recorded in deuterated chloroform (CDCl₃) or Dimethyl Sulfoxide-deutrated6 (DMSO-d6) at either Faculty of Pharmacy, Benisweef University, on Bruker Avance III 400 MHz for ¹H and 100 MHz for ¹³C (Bruker AG, Switzerland) with BBFO Smart Probe and Bruker 400 AEON Nitrogen-Free Magnet, and Topspin 3.1 software for data analysis, or at Faculty of Science, Cairo University, on Varian Mercury VX-300 NMR spectrometer, run at 300 MHz for ¹H and at 75.46 MHz for ¹³C. Chemical shifts are quoted in δ (ppm) and were related to that of the solvents.

3.1.2 GC/MS analysis

Method 1: GC/MS analysis was performed at the Central Laboratory of the Ministry of Agriculture, Al Bhooth Str, Cairo, on Agilent 6890 gas chromatograph equipped with an Agilent mass spectrometric column HP-5ms (30 m x 0.32 mm x0.25 µm film thickness). Samples were injected under the following condition: Helium was used as carrier gas at approximately 1 ml /min, pulsed splitless mode. The solvent delay was 3 min and the injection size was 1.0 µl. The mass spectrophotometric detector was operated in electron impact ionization mode with an ionizing energy of 70 eV, scanning from m/z 50 to 500. The ion source temperature was 230°C and the quadruple temperature was 150°C. The electron multiplier voltage (EM voltage) was maintained at 1250 v above auto tune. The instrument was manually tuned using perfluorotributyl amine (PFTBA). The GC temperature program was started at 60°C then elevated to 280°C at rate of 8°C/min. and 10 min. hold at 280°C the detector and injector temperature were set at 280°C and 250°C, respectively. Wiley and Nist 05 mass spectral database was used in the identification of the separated peaks.

Method 2: GC/MS analysis was performed at the National Research Center (NRC), Dokki, Cairo, and on a varian GC interfaced to Finnigan SSQ 7000 Mass Selective Detector (MSD) with ICIS V2.0 data system for MS identification of the GC components. The column used was DB-5 (J & W Scientific, Folsom, CA) cross–linked fused silica capillary column (30 m long, 0.25 mm internal diameter) coated with poly dimethyl siloxane (0.5 μ m film thickness). The oven temperature was programmed from 50°C for 3 min., at isothermal, then heating by 7°C / min. to 250°C and isothermally for 10 min., at 250 °C. Injector temperature was 200°C and the volume injected was 0.5 μ l. Transition–line and ion source temperature were 250°C and 150°C respectively. The mass spectrometer had a delay of

3 min. to permit the solvent plead and then scanned from m/z 50 to m/z 300. Ionization energy was set at 70 ev.

3.2 Materials

3.2.1 Plant material

Abutilon pannosum was collected from Tennidah village, Dakhla oasis, and new valley governorate in western desert on March 2014 by Dr. Maha Elshamy, Botany Department, Faculty of Science, Mansoura University. The leaves were used for investigation.

3.2.2 Cell line

Hepatocellular carcinoma (liver) HePG-2, mammary gland (breast) MCF-7 and Human (prostate) cancer cell line PC3 were obtained from ATCC via Holding company for biological products and vaccines (VACSERA), Cairo, Egypt.

3.2.3 Chemical reagents and solvents

The reagents RPMI-1640 medium, MTT, DMSO, 5fluorouracil (Sigma co., St. Louis, USA) and Fetal Bovine serum (GIBCO, UK) were used for cytotoxicity assessment. Thin layer chromatography and preparative (TLC) were performed on silica gel (Kieselgel 60, GF 254). Silica gel (60-120 Mesh) for column chromatography (Nice Chemicals Co.), Lipophilic sephadex LH-20 for column was obtained from sigma chemical company, hexane was obtained from Alpha Chemika, methylene chloride was obtained from SDFCL SD fine-chem limited; EtOAc, MeOH, BuOH, C₆H₆, (CH₃)₂CO and Na₂SO₄, were obtained from Adowic.

3.2.4 Spray reagent

P-Anisaldehyde-sulphuric acid reagent was prepared freshly by adding conc. sulphuric acid (8 μ l) to solution of p-Anisaldehyde (0.5 μ l) in glacial acetic acid (10 μ l) and methanol (85 μ l). The chromatogram after spraying was heated at 100°C until the spots attained maximum color (Wagner et al., 1984).

3.3 Processing of Abutilon pannosum leaves

The freshly collected plant material of *Abutilon pannosum* was cut into small pieces and air dried in shade at room temperature. After drying the plant material, leaves were ground to give (400.21 g) of dried powdered material, and extracted by soxhlet extractor using different solvents of different polarity; petroleum ether 60-80, methylene chloride and methanol respectively to attain three fractions: petroleum ether fraction (Ap A, 10.920 g), Methylene chloride fraction (Ap B, 3.355 g), and Methanol fraction (Ap C, 14.974 g).The Butanol fraction (Ap D, 7.043g) separated from Methanol fraction.

3.3.1 Processing of petroleum ether fraction (Ap A)

A sample from Ap A fraction (0.816 g) was analyzed by GC/MS using method 1. Then, the fraction Ap A (10.104 g) was defatted through dissolving in cold methanol to obtain defatted part (1.752 g). A part of which (1.152 g) was subjected to column chromatography over silica gel using a series of eluents from petroleum ether / ethyl acetate combinations of

increase polarity. Ninety-five sub fraction were collected from the column and by inspecting their TLC, five sub-fractions (14a, 17a, 78a, 85a, and 90a) were chosen to ¹H-NMR, and according to the results of ¹H-NMR, the sub fraction (14a, 0.317 g) was chosen for GC/MS analysis by method 2 as (Ap a) .The remaining part (0.513 g) was used for biological activity.

3.3.1.1 Chemical composition of fraction (Ap A) by GC/MS

petroleum ether Fraction Ap A afforded by GC/MS using method 1 n-undecane (2) (Rt= 9.22 min., 0.55%), n-dodecane (3) (R_t = 11.18 min., 0.57%), 2-methyldodecane (21) (R_t = 12.34 min., 0.25%), 2,6-dimethyldodecane (24) (Rt= 12.49 min., 0.44%), n-tridecane (4) (Rt= 12.99 min., 01.65%), ntetradecane (5) (Rt= 14.69 min., 2.62%), phytane (43) (Rt= 15.68 min., 1.65%), n-pentadecane (6) (R_t= 16.28 min., 4.79%), n-hexadecane (7) (R_t= 17.78 min., 6.54%), 2-methyl hexadecane (22) (R_t= 18.67 min., 1.97%), n-heptadecane (8) (Rt= 19.20 min., 7.29%), 1-methyl-9H-fluorine (53) (Rt= 19.49 min., 1.79%), n-octadecane (9) (R_t= 20.55 min., 7.31%), 3methyloctadecane (23) (Rt= 21.35 min., 3.75%), n-nonadecane (10) (R_t = 21.83 min., 8.28%), n-hexadecanoic acid (25) (R_t = 22.67 min., 5.78%), n-eicosane (11) (Rt= 23.05 min., 7.63%), n-heineicosane (12) (R_t= 24.21 min., 5.39%), phytol (46) (R_t= 24.41 min., 3.09%), methyllinolenate (31) (Rt= 24.76 min., 4.15%), n-docosane (13) (R_t= 25.33 min., 4.69%), 14-β-Hpregnane (45) (Rt= 25.54 min., 1.68%), n-tricosane (14) (Rt= 26.40 min., 3.63%), n-tetracosane (15)

 $(R_t=27.43 \text{ min.}, 3.21\%)$, n-pentacosane (16) $(R_t=28.41 \text{ min.}, 3.34\%)$, n-hexacosane (17) $(R_t=29.36 \text{ min.}, 1.95\%)$, n-heptacosane (18) $(R_t=30.28 \text{ min.}, 1.40\%)$, n-octacosane (19) $(R_t=31.21 \text{ min.}, 0.79\%)$, squalene (50) $(R_t=31.60 \text{ min.}, 2.78\%)$, n-nonacosane (20) $(R_t=32.27 \text{ min.}, 0.70\%)$ and vitamin E (51) $(R_t=35.85 \text{ min.}, 0.50\%)$.

3.3.1.2 Chemical composition of sub-fraction (Ap a) by GC/MS

Petroleum ether sub-fraction (Ap a) afforded by GC/MS using method 2 methyl octadeca-12,15-diynoate (30) (Rt= 30.93 min., 2.82%), methyl octadeca-10,13-diynoate (29) (Rt= 32.87 min., 1.61%), n-octadecane (9) (Rt= 36.64 min., 6.26%), nnonadecane (10) (R_t = 39.11 min., 8.48%), methylpalmitate (28) 38.98%), 2-[4-methyl-6-(2,6,6- $(R_t =$ 39.83 min., trimethylcyclohex-1-enyl)hexa-1,3,5-trienyl]cyclohex-1-en-1carboxaldehyde (48) (Rt= 40.00 min., 1.21%), n-eicosane (11) $(R_t = 41.47 \text{ min.}, 8.28\%)$, n-heineicosane (12) $(R_t = 43.76 \text{ min.}, 8.28\%)$ 8.08%), methyllinolenate (31) (Rt= 43.87 min., 5.65%), methyl stearate (32) (Rt= 44.42 min., 1.61%), n-docosane (13) (Rt= 45.93 min., 5.85%), n-tricosane (14) (R_t = 48.02 min., 4.24%), n-tetracosane (15) (R_t= 50.03 min., 3.23%), n-pentacosane (16) (Rt= 51.96 min., 2.22%) and n-hexacosane (17) (Rt= 53.83 min., 1.41%).

3.3.2 Processing of methylene chloride fraction (*Ap B*)

A sample from Ap B fraction (0.683 g) was analyzed by GC/MS using method 1, a part from it (2.005 g) was subjected

to column chromatography over silica gel using a series of eluents from hexane / ethyl acetate combinations of increase polarity. Fifty-eight sub-fraction were collected from the column and by inspecting their TLC, nine sub fractions (5b, 7b, 12b, 16b, 20b, 25b, 35b, 41b and 43b) were chosen to ¹H-NMR, and according to the results of ¹H-NMR, the sub-fractions (5b, 7b, 0.483 g) were mixed together as (Ap b) and were chosen for GC/MS analysis by method 2. The samples (16b, 25b) were mixed together and subjected to reversed phase column according to ¹H-NMR results but no any benefit results were obtained. The remaining part (0.497 g) was used for biological activity.

3.3.2.1 Chemical composition of fraction (Ap B) by GC/MS

Methylene chloride fraction Ap B afforded by GC/MS using method 1 n-tetradecane (5) (Rt= 14.67 min., 0.33%), npentadecane (6) (R_t= 16.26 min., 0.85%), dehydroxyloliolide (33) (R_t = 17.08 min., 0.39%), n-hexadecane (7) (R_t = 17.75 min., 1.6%), crocetane (43) (Rt= 18.45 min., 0.82%), 2-methyl hexadecane (22) (R_t= 18.65 min., 0.28%), n-heptadecane (8) $(R_t = 19.16 \text{ min.}, 1.85\%)$, pristine (40) $(R_t = 19.25 \text{ min.}, 1.36\%)$, loliolide (35) (Rt= 20.42 min., 1.01%), n-octadecane (9) (Rt= 20.51 min., 2.64%), neophytadiene (42) (Rt= 21.04 min., 5.58%), 2,6,10-trimethyldodecane (38) (R_t= 21.13 min., 1.06%), n-nonadecane (10) (Rt=21.79 min., 2.32%), methyl palmitate (28) (Rt= 22.12 min., 1.36%), n-hexadecanoic acid (25) (Rt= 22.61 min., 4.97%), n-eicosane (11) (Rt= 23.01 min., 3.27%), n-heneicosane (12) (R_t= 24.18 min., 2.73\%), methyllinolenate (31) (Rt= 24.26 min., 0.43%), phytol (46) (Rt= 24.39 min., 31.69%), 9-octadecenoic acid (26) (Rt= 24.73 min., 2.75%), n-docosane (13) (R_t= 25.30 min., 2.79%), ntricosane (14) (R_t= 26.37 min., 2.54%), 4,8,12,16-tetramethyl heptadecan-1,4-olide (47) (Rt= 27.03 min.,1.29%), geranyl acetone (34) (Rt= 27.33 min., 0.55%), n-tetracosane (15) (Rt= 27.40 min., 3.04%), n-pentacosane (16) (Rt= 28.39 min., 2.24%), squalene (50) (Rt = 31.58 min., 15.76%), vitamin E (51) (Rt= 35.58 min., 3.00%) and gibberellin A3 (49) (Rt= 38.41 min., 1.31%).

3.3.2.2 Chemical composition of sub-fraction (Ap b) by GC/MS

Methylene chloride-sub fraction (Ap b) afforded by GC/MS using method 2 4(15),6-cadinadiene (37) (Rt= 24.46 min., 1.76%), trans-β-caryophyllene (36) (R_t= 25.83 min., 5.67%), nhexadecane (7) (R_t= 27.13 min., 4.44%), phytol (46) (R_t= 37.57 min., 1.82%), 6,10,14-trimethyl-2-pentadecanone (41) (R_t= 37.75 min., 13.27%), methyl 14-methylpentadecanoate (27) (R_t= 39.91 min., 4.63%), dioctyladipate (54) (R_t= 50.11 min., 4.88%), squalene (50) (R_t= 57.94 min., 61.71%) and 3,4,3',4'tetrahydrospirilloxanthin (52) (R_t= 60.99 min., 1.76%).

3.3.3 Processing of methanol fraction (Ap C)

Methanol fraction (Ap C, 13.651 g) was portioned between water and butanol in separating funnel. The butanol layer was evaporated to dryness affording (ApD, 7.043 g). A sample from (ApD, 3.907 g) was subjected to silica gel column using methanol / methylene chloride eluents of increase polarity. The sub-fractions were subjected to sephadex LH-20 column using methanol solvent as eluent, followed by TLC purification with eluent system ethyl acetate (9.1 ml) / methanol (0.6 ml) / water (0.3 ml) to give **1** (594 mg, R_f = 0.65).

3.4Biological applications

3.4.1 Antimicrobial activity assessment

The three fractions and the isolated compound were individually tested against a panel of gram positive (*Staphylococcus aureus*), gram negative (*Escherichia coli*) bacterial and the fungus (*Candida albicans*). Each of the fractions and the isolated compound was dissolved in DMSO and solution of the concentration 1 mg / ml were prepared separately. Paper discs of Whatman filter paper were prepared with standard size (5 mm diameter), were cut and sterilized in

an autoclave. The paper discs were soaked in the desired concentration of the extract solution and placed aseptically in the Petri-dishes containing nutrient agar media (agar 20 g + beef extract 3 g + peptone 5 g) seeded with *Staphylococcus aureus, Escherichia coli* and *Candida albicans*. The Petri dishes were incubated at 36°C and the inhibition zones were recorded after one day of incubation. Each treatment was replicate 3 times. The antibacterial activities of a common standard antibiotics *ampicillin, gentamicin and amphotericin B* were also recorded using the same procedure as above at the same concentration and solvents. The % activity index for each treatment was calculated by the formula:

% Activity Index

```
= \frac{Zone \ of \ inhibition \ by \ test \ extract \ (diametre)}{Zone \ of \ inhibition \ by \ standard \ (diametre)} x \ 100
```

Table 5: The MS data of compounds identified by GC/MS

Compound name and number		MS Data : <i>m</i> / <i>z</i> [identity](rel. abound.%)
2	n-undecane	156 $[M^+]$ (5.0%), 127 $[M-C_2H_5]^+$ (1.7%), 113 $[M-C_3H_7]^+$ (3.3%), 99 $[M-C_4H_9]^+$ (6.6%), 85 $[M-C_4H_9]^+$
		$C_{5}H_{11}^{+}(33.3\%), 71 [M-C_{6}H_{13}]^{+}(53.3\%), 57 [M-C_{7}H_{15}]^{+}(100\%)$
3	n-dodecane	170 [M ⁺] (5.0%), 141 [M-C ₂ H ₅] ⁺ (1.0%), 127 [M-C ₃ H ₇] ⁺ (1.7%), 113 [M-C ₄ H ₉] ⁺ (4.0%), 99 [M-
		$C_{5}H_{11}^{+}$ (6.7%), 85 [M-C $_{6}H_{13}^{+}$ (37.3%), 71 [M-C $_{7}H_{15}^{+}$ (60.0%), 57 [M-C $_{8}H_{17}^{+}$ (100%)
4	n-tridecane	184 [M ⁺] (4.3%), 141 [M-C ₃ H ₇] ⁺ (3.3%), 127 [M-C ₄ H ₉] ⁺ (3.0%), 113 [M-C ₅ H ₁₁] ⁺ (4.0%), 99 [M-
		$C_{6}H_{13}]^{+}$ (8.3%), 85 $[M-C_{7}H_{15}]^{+}$ (44.3%), 71 $[M-C_{8}H_{17}]^{+}$ (67.7%), 57 $[M-C_{9}H_{19}]^{+}$ (100%)
5	n-tetradecane	198 [M ⁺] (3.3%), 173 (0.3%), 160 (1.3%), 145 (3.3%), 127 [M-C ₅ H ₁₁] ⁺ (3.3%), 113 [M-C ₆ H ₁₃] ⁺
		$(5.0\%), 99 [M-C_7H_{15}]^+ (10.3\%), 85 [M-C_8H_{17}]^+ (50.0\%), 71 [M-C_9H_{19}]^+ (70.7\%), 57 [M-C_{10}H_{21}]^+$
		(100%)
6	n-pentadecane	212 [M ⁺] (4.0%), 183 [M-C ₂ H ₅] ⁺ (0.7%), 169 [M-C ₃ H ₇] ⁺ (1.0%), 155 [M-C ₄ H ₉] ⁺ (2.7%), 141 [M-
		$C_{5}H_{11}^{+}$ (3.3%), 127 [M-C ₆ H ₁₃] ⁺ (4.0%), 113 [M-C ₇ H ₁₅] ⁺ (6.7%), 99 [M-C ₈ H ₁₇] ⁺ (13.3%), 85 [M-C_8H_{17}]^+
		$C_{9}H_{19}^{+}$ (52.3%), 71 [M- $C_{10}H_{21}^{+}$ (73.3%), 57 [M- $C_{11}H_{23}^{+}$ (100%)
7	n-hexadecane	226 [M ⁺] (3.3%), 197 [M-C ₂ H ₅] ⁺ (0.3%), 182 (3.7%), 170 (13.3%), 155 [M-C ₅ H ₁₁] ⁺ (16.7%), 141
		$[M-C_{6}H_{13}]^{+}(4.0\%), 127 [M-C_{7}H_{15}]^{+}(6.7\%), 113 [M-C_{8}H_{17}]^{+}(9.3\%), 99 [M-C_{9}H_{19}]^{+}(16.7\%), 85 [M-C_{9}H_{13}]^{+}(16.7\%), 85$
		$C_{10}H_{21}^{+}$ (52.3%), 71 [M-C ₁₁ H ₂₃] ⁺ (76.7%), 57 [M-C ₁₂ H ₂₅] ⁺ (100%)
8	n-heptadecane	240 [M ⁺] (3.3%), 197 [M-C ₃ H ₇] ⁺ (3.3%), 185[M-C ₄ H ₉] ⁺ (3.3%), 169 [M-C ₅ H ₁₁] ⁺ (6.7%), 141 [M-C ₅ H ₁₁] ⁺ (6.7%),
		$C_{7}H_{15}^{+}$ (6.0%), 127 [M-C ₈ H ₁₇] ⁺ (6.7%), 99 [M-C ₁₀ H ₂₁] ⁺ (16.7%), 85 [M-C ₁₁ H ₂₃] ⁺ (60.0%), 71 [M-C ₁₀ H ₂₁] ⁺ (16.7%), 85 [M-C ₁₁ H ₂₃] ⁺ (60.0%), 71 [M-C ₁₀ H ₂₁] ⁺ (16.7%), 85 [M-C ₁₁ H ₂₃] ⁺ (16.7\%), 85 [M-C ₁₁ H ₂₃] ⁺ (16.7\%), 85 [M-C ₁₁ H ₂₃] ⁺ (16.7\%), 85 [M-C ₁₁
		$C_{12}H_{25}]^+$ (80.0%), 57 [M-C ₁₃ H ₂₇] ⁺ (100%)
9	n-octadecane	254 [M ⁺] (3.3%), 211 [M-C ₃ H ₇] ⁺ (0.7%), 178 (6.7%), 155 [M-C ₇ H ₁₅] ⁺ (3.3%), 141 [M-C ₈ H ₁₇] ⁺
		$(4.7\%), 127 [M-C_9H_{19}]^+ (6.7\%), 113 [M-C_{10}H_{21}]^+ (10.7\%), 99 [M-C_{11}H_{23}]^+ (18.7\%), 85 [M-C_{12}H_{25}]^+$
		$(60.0\%), 71 [M-C_{13}H_{27}]^+ (80.0\%), 57 [M-C_{14}H_{29}]^+ (100\%)$
10	n-nonadecane	$268 [M^+] (3.3\%), 197 [M-C_5H_{11}]^+ (2.6\%), 141 [M-C_9H_{19}]^+ (6.3\%), 127 [M-C_{10}H_{21}]^+ (8.0\%), 113 [M-C_1H_{21}]^+ (8.0\%), 113 [M-C_2H_{11}]^+ (8.0\%), 113 [M-$
		$C_{11}H_{23}^{+}$ (12.3%), 99 [M- $C_{12}H_{25}^{+}$ (16.7%), 85 [M- $C_{13}H_{27}^{+}$ (62.7%), 71 [M- $C_{14}H_{29}^{+}$ (80.0%), 57
		$[M-C_{15}H_{31}]^+$ (100%)
11	n-eicosane	$282 \ [M^+] \ (3.3\%), 197 \ [M-C_6H_{13}]^+ \ (3.3\%), 155 \ [M-C_9H_{19}]^+ \ (4.0\%), 141 \ [M-C_{10}H_{21}]^+ \ (6.7\%), 127 \ [M-C_{10}H_{10}]^+ \ (6.7\%)$
		$C_{11}H_{23}^{+}$ (9.3%), 113 [M-C ₁₂ H ₂₅] ⁺ (13.0%), 99 [M-C ₁₃ H ₂₇] ⁺ (20.0%), 85 [M-C ₁₄ H ₂₉] ⁺ (64.0%), 71
		$[M-C_{15}H_{31}]^+$ (80.3%), 57 $[M-C_{16}H_{33}]^+$ (100%)
12	n-heineicosane	296 [M ⁺] (3.0%), 253 [M-C ₃ H ₇] ⁺ (0.7%), 239 [M-C ₄ H ₉] ⁺ (1.3%), 225 [M-C ₅ H ₁₁] ⁺ (1.0%), 211 [M-C ₄ H ₉] ⁺ (1.3%), 253 [M-C ₅ H ₁₁] ⁺ (1.0%), 211 [M-C ₄ H ₉] ⁺ (1.3%), 253 [M-C ₅ H ₁₁] ⁺ (1.0%), 211 [M-C ₅ H ₁₁] ⁺ (1.0%),
		$C_{6}H_{13}^{+}$ (1.3%), 197 [M-C ₇ H ₁₅] ⁺ (2.3%), 183 [M-C ₈ H ₁₇] ⁺ (3.0%), 169 [M-C ₉ H ₁₉] ⁺ (3.7%), 155 [M-C ₉ H ₁₉] ⁺ (3.7%), 150 [M-C ₉ H ₁₉] ⁺ (3.7%), 150 [M-C ₉ H ₁₉]
		$C_{10}H_{21}$] ⁺ (4.7%), 141 [M- $C_{11}H_{23}$] ⁺ (6.7%), 127 [M- $C_{12}H_{25}$] ⁺ (9.3%), 113 [M- $C_{13}H_{27}$] ⁺ (13.3%), 99
10		$[M-C_{14}H_{29}]^+(24.0\%), 85 [M-C_{15}H_{31}]^+(65.7\%), 71 [M-C_{16}H_{33}]^+(83.3\%), 57 [M-C_{17}H_{35}]^+(100\%)$
13	n-docosane	$[310 \ [M^+] \ (1.3\%), 288 \ (0.3\%), 253 \ [M-C4H_9]^+ \ (0.7\%), 225 \ [M-C_6H_{13}]^+ \ (0.7\%), 211 \ [M-C_7H_{15}]^+$
		(0.7%), 185 [M-C9H19] ⁺ (3.3%), 155 [M-C11H23] ⁺ (4.7%), 127 [M-C13H27] ⁺ (10.0%), 113 [M-C14H29] ⁺ (12.2%) 0.0 PL G H = 1+ (22.2%) 0.0 PL G H
		$\begin{bmatrix} J^{+} (15.5\%), 99 \ [M-C_{15}H_{31} \]^{+} (21.7\%), 85 \ [M-C_{16}H_{33} \]^{+} (83.3\%), 71 \ [M-C_{17}H_{35} \]^{+} (83.0\%), 57 \ [M-C_{16}H_{13} \]^{+} (100\%) \end{bmatrix}$
		$C_{18}H_{37}$] ⁺ (100%)

14	n-tricosane	324 [M ⁺] (2.7%), 281 [M-C ₃ H ₇] ⁺ (0.3%), 253 [M-C ₅ H ₁₁] ⁺ (0.3%), 225 [M-C ₇ H ₁₅] ⁺ (0.3%), 197 [M-
		$C_{9}H_{19}^{+}$ (2.7%), 169 [M- $C_{11}H_{23}^{+}$ (3.7%), 155 [M- $C_{12}H_{25}^{-}$] ⁺ (6.0%), 141 [M- $C_{13}H_{27}^{-}$] ⁺ (6.7%), 127
		$[M-C_{14}H_{29}]^+(10.0\%), 113 [M-C_{15}H_{31}]^+(13.7\%), 99 [M-C_{16}H_{33}]^+(23.0\%), 85 [M-C_{17}H_{35}]^+(70.0\%),$
		71 $[M-C_{18}H_{37}]^+$ (83.3%), 57 $M-C_{19}H_{39}]^+$ (100%)
15	n-tetracosane	338 [M ⁺] (1.3%), 281 [M-C ₄ H ₉] ⁺ (0.7%), 253 [M-C ₆ H ₁₃] ⁺ (0.7%), 225 [M-C ₈ H ₁₇] ⁺ (0.7%), 197 [M-
		$C_{10}H_{21}^{+}$ (3.0%), 169 $[M-C_{12}H_{25}]^{+}$ (3.7%), 155 $[M-C_{13}H_{27}]^{+}$ (6.3%), 141 $[M-C_{14}H_{29}]^{+}$ (7.0%), 127
		$[M-C_{15}H_{31}]^+$ (10.3%), 113 $[M-C_{16}H_{33}]^+$ (14.0%), 99 $[M-C_{17}H_{35}]^+$ (23.0%), 85 $[M-C_{18}H_{37}]^+$ (70.0%),
		71 M-C ₁₉ H ₃₉] ⁺ (83.3%), 57 M-C ₂₀ H ₄₁] ⁺ (100%)
16	n-pentacosane	352 [M ⁺] (1.0%), 323 [M-C ₂ H ₅] ⁺ (0.3%), 281 [M-C ₅ H ₁₁] ⁺ (0.7%), 253 [M-C ₇ H ₁₅] ⁺ (0.7%), 225 [M-
	I	$C_{9}H_{19}^{+}(0,7\%)$, 197 [M-C ₁₁ H ₂₃] ⁺ (3.0%), 169 [M-C ₁₃ H ₂₇] ⁺ (3.7%), 155 [M-C ₁₄ H ₂₉] ⁺ (6.3%), 141
		$[M-C_{15}H_{31}]^+(7.0\%), 127 [M-C_{16}H_{33}]^+(10.3\%), 113 [M-C_{17}H_{35}]^+(14.0\%), 99 [M-C_{18}H_{37}]^+(23.0\%),$
		85 [M-C ₁₉ H ₃₉] ⁺ (70.0%), 71 [M-C ₂₀ H ₄₁] ⁺ (83.3%), 57 M-C ₂₁ H ₄₃] ⁺ (100%)
17	n-hexacosane	$366 [M^+] (0.7\%), 309 [M-C_5H_{11}]^+ (0.3\%), 281 [M-C_6H_{13}]^+ (2.7\%), 253 [M-C_7H_{15}]^+ (2.7\%), 225 [M-C_7H_{15}]^+ (2.7\%), 255 [M-C_7$
- /		$C_{10}H_{21}I^+$ (2.7%), 197 [M-C ₁₂ H ₂₅] ⁺ (3.0%), 169 [M-C ₁₄ H ₂₉] ⁺ (4.0%), 141 [M-C ₁₆ H ₃₃] ⁺ (7.0%), 127
		$[M-C_{17}H_{35}]^+$ (10 3%) 113 $[M-C_{19}H_{37}]^+$ (14 0%) 99 $[M-C_{19}H_{30}]^+$ (23 3%) 85 $[M-C_{20}H_{41}]^+$ (66 7%)
		$71[M-C_{21}H_{42}]^+$ (83.3%) 57 $[M-C_{22}H_{45}]^+$ (100%)
18	n-hentacosane	$\frac{1}{10000} = \frac{1}{10000} = \frac{1}{10000} = \frac{1}{10000} = \frac{1}{10000} = \frac{1}{10000} = \frac{1}{10000} = \frac{1}{100000} = \frac{1}{100000} = \frac{1}{10000000000000000000000000000000000$
10	n neptucosune	(3.0%) 267 [M-C ₂ H ₁₇] ⁺ (0.4%) 225 [M-C ₁₁ H ₂₂] ⁺ (1.3%) 211 [M-C ₁₂ H ₂₂] ⁺ (3.3%) 107 [M-C ₁₂ H ₂₇] ⁺
		(3.3%) 169 [M-C ₁₂ H ₂₁] ⁺ (4.3%) 141 [M-C ₁₂ H ₂₂] ⁺ (7.0%) 113 [M-C ₁₂ H ₂₂] ⁺ (14.7%) 99 [M-C ₂₀ H ₄₁] ⁺
		(3.5%), 100 [W-C ₁₅₁₁₃₁] (4.5%), 141 [W-C ₁₇₁₃₅] (7.6%), 113 [W-C ₁₉₁₃₉] (14.7%), 97 [W-C ₂₀₁₄₁] (4.5%), 100 [W-C ₁₅₁₁₃₁] (4.5%), 141 [W-C ₁₇₁₃₅] (7.6%), 113 [W-C ₁₉₁₃₉] (14.7%), 97 [W-C ₂₀₁₄₁]
10	n octacosana	$\begin{array}{c} 304 \text{ [M^+]} (0.3\%) & 355 (0.3\%) & 300 \text{ [M} \text{ C}_{2}\text{H}_{2}\text{l}^{+} (0.7\%) & 381 \text{ [M} \text{ C}_{2}\text{H}_{1}\text{l}^{+} (6.2\%) & 253 \text{ [M} \text{ C}_{2}\text{H}_{2}\text{l}^{+} \\ \end{array}$
19	II-Octacosane	(2.0%) 225 [M ($_{12}$)] (0.5%), 505 (0.5%), 509 [M-C ₀]] (0.7%), 201 [M-C ₀]] (0.5%), 205 [M-C ₀]] (121]
		(5.0%), 225 [M-C12H25] $(2.7%), 207$ [M-C14H19] $(15.0%), 109$ [M-C16H33] $(4.5%), 141$ [M-C18H37] (4.5%), 141 [M-C18H37] $(4.5%), 141$ [M-C18
		$\int (7.0\%), 127 [W-C19ff39] (10.5\%), 115 [W-C20ff41] (14.5\%), 99 [W-C21ff43] (25.5\%), 85 [W-C21ff43] ($
20		$\begin{array}{c} C_{22}H_{45} & (0.5.5\%), 71 \left[M^{-}C_{23}H_{47} \right] & (80.5\%), 57 \left[M^{-}C_{24}H_{49} \right] & (100\%) \\ \hline \\ AOS \left[M^{+1} & (0.2\%) \right] & 255 & (0.7\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.7\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{-}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[M^{+}C \right] & 1^{+} & (0.2\%) \\ \hline \\ AOS \left[$
20	n-nonacosane	$408 \text{ [M^{-}]} (0.5\%), 555 (0.7\%), 509 \text{ [M-C7H15]}^{\circ} (0.7\%), 281 \text{ [M-C9H19]}^{\circ} (0.5\%), 255 \text{ [M-C11H23]}^{\circ}$
		$(5.0\%), 225$ [M-C ₁₃ π_{27}] ⁺ $(0.7\%), 207$ [M-C ₁₅ π_{21}] ⁻ $(10.7\%), 109$ [M-C ₁₇ π_{35}] ⁺ $(5.7\%), 141$ [M-C ₁₉ π_{39}] ⁺ $(8.2\%), 127$ [M-C ₁₄] ⁺ $(11.0\%), 112$ [M-C ₁₄] ⁺ $(16.0\%), 00$ [M-C ₁₄] ⁺ $(12.2\%), 85$ [M-C ₁₄] ⁺ $(12.2\%), 127$ [M-C ₁₄] ⁺ $(1$
		$\begin{bmatrix} (0.5\%), 127 \\ [W-C_{20}] + (25.5\%), 05 \\ [W-C_{21}] + (25.5\%), 05 \\ [W-C_{21}] + (25.5\%), 05 \\ [W-C_{22}] + (25.5\%), 05 \\ [W-$
0.1	2 1 1 1	$C_{23}H_{47}$] (64.5%), /1 [M-C ₂₄ H ₄₉] (85.5%), 5/ [M-C ₂₅ H ₅₁] (100%)
21	2-methyldodecane	184 $[M^+]$ (0.3%), 169 $[M-CH_3]^+$ (6.7%), 141 $[M-C_3H_7]^+$ (13.5%), 127 $[M-C_4H_9]^+$ (3.3%), 113 $[M-C_4H_9]^+$ (3.3\%), 1
		$C_{5}H_{11}$ (8.3%), 99 [M-C ₆ H ₁₃] (19.7%), 85 [M-C ₇ H ₁₅] (60.0%), 71 [M-C ₈ H ₁₇] (76.7%), 57 [M-C ₁ H ₁₅] (19.7%)
22		C_9H_{19}]' (100%)
22	2-methylnexadecane	240 [M ⁺] (0.2%), 225 [M-CH ₃] ⁺ (4.1%), 197 [M-C ₃ H ₇] ⁺ (13.3%), 184 [M-C ₄ H ₈] ⁺ (10.0%), 169 [M-C ₄ H ₈] ⁺ (10.0%), 160 [M-C ₄ H ₈] ⁺ (10.0%),
		C_{5H11}^{-1} (8.5%), 155 [M-C_{6H13}] (15.5%), 141 [M-C_{7H15}] (10.0%), 127 [M-C_{8H17}] (15.5%), 115
		$[M-C_9H_{19}]^{+}(10.7\%), 99 [M-C_{10}H_{21}]^{+}(22.7\%), 85 [M-C_{11}H_{23}]^{+}(54.3\%), 71 [M-C_{12}H_{25}]^{+}(64.3\%), 57$
		[M-C13H27] ⁺ (100%)
23	3-methyloctadecane	268 $[M^+]$ (0.3%), 253 $[M-CH_3]^+$ (3.3%), 239 $[M-C_2H_5]^+$ (1.0%), 211 $[M-C_4H_9]^+$ (3.3%), 197 $[M-C_4H_9]^+$ (3.3\%)
		$C_{5}H_{11}^{\dagger}$ (4.0%), 183 [M-C ₆ H ₁₃] ⁺ (7.7%), 169 [M-C ₇ H ₁₅] ⁺ (11.3%), 155 [M-C ₈ H ₁₇] ⁺ (10.0%), 141
		$[M-C_9H_{19}]^+$ (10.7%), 127 $[M-C_{10}H_{21}]^+$ (11.0%), 113 $[M-C_{11}H_{23}]^+$ (13.3%), 99 $[M-C_{12}H_{25}]^+$ (21.7%),
		85 $[M-C_{13}H_{27}]^+$ (56.0%), 71 $[M-C_{14}H_{29}]^+$ (70.7%), 57 $[M-C_{15}H_{31}]^+$ (100%)
24	2,6-dimethyldodecane	198 [M ⁺] (0.75%), 183 [M-CH ₃] ⁺ (0.2%), 155 [M-C ₃ H ₇] ⁺ (1.3%), 141 [M-C ₄ H ₉] ⁺ (1.0%), 127 [M-
		$C_{5}H_{11}^{+}$ (2.7%), 113 [M-C ₆ H ₁₃] ⁺ (16.7%), 85 [M-C ₇ H ₁₅] ⁺ (14.3%), 71 [M-C ₉ H ₁₉] ⁺ (92.7%), 57
		(100%)
25	n-hexadecanoic acid	256 [M ⁺] (29.3%), 241 [M-CH ₃] ⁺ (0.7%), 227 [M-C ₂ H ₅] ⁺ (9.0%), 213 [M-C ₃ H ₇] ⁺ (10.5%), 199 [M-C ₃ H ₇] ⁺ (10.5%), 190 [M-C ₃ H ₇] ⁺ (10.5%),
		$C_{4}H_{7}^{+}$ (10.0%), 185 [M-C ₅ H ₁₁] ⁺ (21.3%), 171 [M-C ₆ H ₁₃] ⁺ (21.0%), 157 [M-C ₇ H ₁₅] ⁺ (23.3%), 143
		$[M-C_{8}H_{17}]^{+}(11.3\%), 139 [M-C_{4}H_{9}]^{+}(3.3\%), 129 [M-C_{9}H_{19}]^{+}(56.7\%), 115 [M-C_{10}H_{21}]^{+}(22.7\%), 97$
		$[M-C_7H_{15}]^+$ (37.0%), 85 $[M-C_8H_{15}]^+$ (39.3%), 83 $[M-C_8H_{17}]^+$ (46.7%), 73 $[M-C_{13}H_{27}]^+$ (100%), 57
		$[M-C_{10}H_{19}]^+$ (82.0%), 55 $[M-C_{10}H_{21}]^+$ (66.7%)
0.5		
26	9-octadecenoic acid	282 [M ⁺] (0.3%), 265 [M-OH] ⁺ (3.3%), 223 [M-C ₂ H ₃ O ₂] ⁺ (0.3%), 181 [M-C ₅ H ₉ O ₂] ⁺ (0.3%), 153 [M-
		$C_7H_{13}O_2$ ^T (3.3%), 99 [M-C ₁₁ H ₁₉ O ₂] ⁺ (4.0%), 85 [M-C ₁₂ H ₂₁ O ₂] ⁺ (13.35), 55 (100%), 43 [M-C_12H_2O_2] ⁺ (13.35), 55 (100%), 55 (100%), 55 (100%), 55 (100%), 55 (100%), 55 (100%), 55 (100%), 55 (100%), 55 (100%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 55 (100\%), 5
		$C_{15}H_{27}O_2]^+$ (53.3%)
27	methyl-14-	270 [M ⁺] (40.6%), 241 (13.1%), 227 (29.8%), 199 [M-C ₃ H ₅ O ₂] ⁺ (12.0%), 187 (13.5%), 149 (20.1%),
	methylpentadecanoate	135 (31.6%), 129 $[M-C_{10}H_{21}]^+$ (24.8%), 87 $[M-C_{13}H_{27}]^+$ (100%), 69 (83.5), 57 $[M-C_{13}H_{25}O_2]^+$
		(38.4%)
28	methylpalmitate	270 [M ⁺] (13.3%), 239 [M-CH ₃ O] ⁺ (4.73%), 227 [M-C ₃ H ₇] ⁺ (10.0%), 213 [M-C ₄ H ₉] ⁺ (3.0%), 199

		$[M-C_9H_{19}]^+$ (18.0%), 129 $[M-C_{10}H_{21}]^+$ (6.7%), 115 $[M-C_{11}H_{23}]^+$ (3.3%), 97 $[M-C_{12}H_{25}]^+$ (6.7%), 87
		[M-C ₁₃ H ₂₇] ⁺ (70.0%), 74 (100%), 55 (30.0%), 43 (40.0%), 29 (3.3%)
29	methyloctadeca-10,13-	$290 \ [M^+] \ (0.2\%), 284 \ (0.2\%), 231 \ [M-C_2H_3O_2]^+ \ (2.6\%), 203 \ [M-C_4H_7O_2]^+ \ (6.4\%), 147 \ [M-C_8H_{15}O_2]^+ \ (0.2\%), 203 \ [M-C_4H_7O_2]^+ \ (0.2\%), 203 \ [M-C_8H_{15}O_2]^+ \ (0.2\%), 203 \ [M-C_8H_{15}O_2]$
	diynoate	(7.7%) , 133 $[M-C_9H_{17}O_2]^+$ (35.4%), 119 $[M-C_{10}H_{19}O_2]^+$ (14.3%), 105 $[M-C_{11}H_{21}O_2]^+$ (68.0%), 91
	•	$(100\%), 69 [M-C_{14}H_{21}O_2]^+ (11.0\%), 57 [M-C_{15}H_{21}O_2]^+ (17.6\%)$
30	methyloctadeca-12,15-	290 [M ⁺] (0.2%), 259 [M-CH ₃ O] ⁺ (0.2%), 232 (6.1%), 203 [M-C ₄ H ₇ O ₂] ⁺ (0.4%), 175 [M-C ₆ H ₁₁ O ₂] ⁺
	diynoate	$(4.6\%), 147 [M-C_8H_{15}O_2]^+ (10.3\%), 119 [M-C_{10}H_{19}O_2]^+ (16.2\%), 105 [M-C_{11}H_{21}O_2]^+ (24.6\%), 91$
	•	$[M-C_{12}H_{13}O_2]^+$ (100%), 69 (11.0%), 57 (16.2%)
31	methyllinolenate	292 [M ⁺] (0.3%), 277 [M-CH ₃] ⁺ (0.3%), 261 [M-CH ₃ O] ⁺ (3.3%), 191 [M-C ₅ H ₉ O ₂] ⁺ (3.3%), 163 [M-
	-	$C_7H_{13}O_2^{+}$ (6.3%), 149 [M-C ₈ H ₁₅ O ₂] ⁺ (16.7%), 135 [M-C ₉ H ₁₇ O ₂] ⁺ (13.7%), 109 [M-C ₁₁ H ₁₉ O ₂] ⁺
		(16.7%) , 95 $[M-C_{12}H_{21}O_2]^+$ (60.0%), 79 (100%), 55 $[M-C_{15}H_{25}O_2]^+$ (46.7%), 29 $[M-C_{17}H_{27}O_2]^+$
		(16.7%)
32	methylstearate	298 [M ⁺] (9.1%), 267 [M-CH ₃ O] ⁺ (2.2%), 255 [M-C ₃ H ₇] ⁺ (6.5%), 199 [M-C ₇ H ₁₅] ⁺ (7.7%), 165
	-	(6.8%) , 143 $[M-C_{11}H_{23}]^+$ (22.6%), 129 (10.8%), 101 $[M-C_{14}H_{29}]^+$ (9.1%), 97 (19.0%), 87 $[M-C_{14}H_{29}]^+$ (9.1%), 97 (19.0%), 87 $[M-C_{14}H_{29}]^+$
		$C_{15}H_{31}^{+}$ (70.4%), 74 (100%), 57 $[M-C_{15}H_{29}O_2]^+$ (36.1%)
33	dehydroxyloliolide	180 [M ⁺] (16.7%), 165 [M-CH ₃] ⁺ (6.7%), 155 (23.3%), 147 (26.7%), 135 (37.3%), 124 (16.7%), 111
		(91.7%), 97 (36.7%), 83 (100%), 69 (56%), 55 (70.0%)
34	geranylacetone	194 [M ⁺] (0.3%), 179 [M-CH ₃] ⁺ (0.7%), 151 [M-C ₂ H ₃ O] ⁺ (0.7%), 137 [M-C ₃ H ₅ O] ⁺ (10.0%), 123 [M-
		C4H7O] ⁺ (8.0%), 83 [M-C7H11O] ⁺ (9.7%), 69 [M-C8H13O] ⁺ (100%), 43 (60.0%)
35	loliolide	196 [M ⁺] (10.3%), 179 [M-OH] ⁺ (9.0%), 163 (30.0%), 153 [M-C ₃ H ₇] ⁺ (20.7%), 140 (36.0%), 125
		(16.7%), 111 (100%), 97 (37.3%), 85 (40.0%), 67 (36.7%), 57 (44.0%)
36	trans-β-caryophyllene	$204 \ [M^+] \ (0.5\%), 189 \ [M-CH_3]^+ \ (11.3\%), 175 \ [M-C_2H_5]^+ \ (18.5\%), 147 \ [M-C_4H_9]^+ \ (54.2\%), 135 \ [M-C_4H_$
		$C_{5}H_{9}]^{+}(27.1\%), 120 [M-C_{6}H_{12}]^{+}(85.8\%), 93 [M-C_{8}H_{15}]^{+}(32.3\%), 79 [M-C_{9}H_{17}]^{+}(100\%), 67 [M-C$
		$C_{10}H_{17}]^+$ (53.3%), 53 [M- $C_{11}H_{19}]^+$ (29.3%)
37	4(15),6-cadinadiene	$204 \ [M^+] \ (25.28\%), 183 \ (3.4\%), 161 \ [M-C_3H_7]^+ \ (100\%), 133 \ (15.8\%), 119 \ [M-C_6H_{13}]^+ \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11.3\%), 105 \ (11$
		$[M-C_7H_{15}]^+$ (68.0%), 93 $[M-C_8H_{15}]^+$ (40.6%), 71 $[M-C_{10}H_{16}]^+$ (26.4%), 57 (32.7%)
38	2,6,10-trimethyldodecane	212 [M ⁺] (3.3%), 197 [M-CH ₃] ⁺ (1.0%), 183 [M-C ₂ H ₅] ⁺ (4.0%), 169[M-C ₃ H ₇] ⁺ (0.1%), 155 [M-
		$C_{4}H_{9}^{+}(3.3\%), 141 [M-C_{5}H_{11}]^{+}(3.3\%), 127 [M-C_{6}H_{13}]^{+}(16.7\%), 113 [M-C_{7}H_{15}]^{+}(11.7\%), 97 [M$
		$C_{8}H_{17}^{+}(21.0\%), 85 \ [M-C_{9}H_{19}^{+}(32.3\%), 71 \ [M-C_{10}H_{21}^{+}(73.3\%), 57 \ [M-C_{11}H_{23}^{+}(100\%), 43 \ [M-C_{10}H_{10}^{+}(100\%), 43 $
		$C_{12}H_{24}]^+$ (83.3%)
39	capnellane-5-α-ol	222 [M ⁺] (17.3%), 207 [M-CH ₃] ⁺ (89.3%), 189 (16.7%), 151 [M-C ₅ H ₁₁] ⁺ (23.6%), 135 (23.3%), 109
		$[M-C_8H_{17}]^+$ (66.0%), 95 $[M-C_9H_{19}]^+$ (84.0%), 81 $[M-C_{10}H_{21}]^+$ (100%), 55 $[M-C_{12}H_{23}]^+$ (59.35)
40	pristine	268 [M ⁺] (0.2%), 232 (0.2%), 197 [M-C ₅ H ₁₁] ⁺ (0.3%), 183 [M-C ₆ H ₁₃] ⁺ (16.7%), 169 [M-C ₇ H ₁₅] ⁺
		$(3.7\%), 155 [M-C_8H_{17}]^+ (6.3\%), 141 [M-C_9H_{19}]^+ (6.0\%), 127 [M-C_{10}H_{21}]^+ (10.0\%), 113 [M-C_{11}H_{23}]^+$
		(20.0%), 99 [M-C ₁₂ H ₂₅] ⁺ (16.7%), 85 [M-C ₁₃ H ₂₇] ⁺ (40.7%), 71 [M-C ₁₄ H ₂₉] ⁺ (93.0%), 57 [M-C ₁₅ H ₃₁] ⁺
		(100%)
41	6,10,14-trimethyl-2-	268 $[M^+]$ (2.9%), 253 $[M-CH_3]^+$ (2.3%), 211 $[M-C_4H_9]^+$ (2.7%), 155 $[M-C_8H_{17}]^+$ (6.8%), 124
	pentadecanone	(38.4%), 109 (63.2%), 95 (31.6%), 85 [M-C ₁₃ H ₂₇] ⁺ (41.1%), 71 [M-C ₁₄ H ₂₉] ⁺ (67.7%), 57 [M-C ₁₄ H ₂₉] ⁺ (67.7%),
10		$C_{15}H_{31}$] ⁺ (59.8%)
42	neophytadiene	278 [M ⁺] (2.7%), 263 [M-CH ₃] ⁺ (0.7%), 208 [M-C ₅ H ₁₀] ⁺ (1.0%), 193 [M-C ₆ H ₁₃] ⁺ (3.0%), 179 [M-C ₆ H ₁] ⁺ (4.2%), 165 PM CH ₂ H + (4.2\%), 165 PM CH ₂ H
		C_7H_{15} (4.7%), 105 [M- C_8H_{17}] (3.3%), 151 [M- C_9H_{19}] (3.3%), 137 [M- $C_{10}H_{21}$] (13.0%), 123 [M- C_1H_1] (6.7%), 100 [M, C_1H_1] (3.3%), 151 [M- C_9H_{19}] (3.3%), 137 [M- $C_{10}H_{21}$] (13.0%), 123 [M-
		$C_{11}H_{23}$ (60.7%), 109 [M- $C_{12}H_{25}$] (33.3%), 95 [M- $C_{13}H_{27}$] (96.7%), 82 [M- $C_{14}H_{28}$] (83.3%), 68
42		$[M-C_{15}H_{30}]^{\circ}$ (100%), 55 $[M-C_{16}H_{31}]^{\circ}$ (00.7%)
43	pnytane	$282 \text{ [M^{-}]} (0.5\%), 197 (1.5\%), 185 \text{ [M-C7H15]}^{\circ} (5.5\%), 109 \text{ [M-C8H17]}^{\circ} (0.5\%), 141 \text{ [M-C10H21]}^{\circ}$
		(10.0%), 127 [M-C1[H23] $(0.7%), 113 (13.7%), 99$ [M-C13H27] $(20.0%), 83$ [M-C14H29] $(34.0%), 71$ [M-C14H29] $(34.0%), 71$ [M-C14H29] $(54.0%), 71$ [M-C14H29] $(54.0%$
44	crocetane	$282 [M^{+1} (0.2\%) 232 (3.0\%) 208 (3.3) 183 [M_C - H_{c}]^{+} (6.7\%) 169 [M_C - H_{c}]^{+} (10.7\%) 155 [M_{c}]^{-}$
44	ciocetalle	$\begin{array}{c} 202 \ [\text{W}] \ (0.2\%), 252 \ (5.0\%), 208 \ (5.5), 105 \ [\text{W}-C/\Pi_{15}] \ (0.7\%), 105 \ [\text{W}-C8\Pi_{17}] \ (10.7\%), 155 \ [W$
		(100%)
45	14-B-H-pregnane	$288 [M^+] (0.3\%) 280 (5.0\%) 250 (11.7\%) 220 (30.7\%) 189 (20.0\%) 165 (20.7\%) 171 (17.0\%)$
-5	1+ p-11-prognano	111 (43.0%) 83 (75.0%) 57 (100%)
46	phytol	$296 [M^+] (0.3\%) 279 [M-OH]^+ (0.3\%) 211 [M-C_{4}H_0O]^+ (0.3\%) 197 [M-C_{4}H_1O]^+ (2.0\%) 123 [M_{-}$
70	Phyton	$C_{12}H_{13}O^{+}$ (22.3%) 111 [M-C_{12}H_{25}O^{+} (13.3%) 95 [M-C_{14}H_{17}O^{+} (16.7\%) 83 [M-C_{12}H_{17}O^{+}]
		(24.0%), 71 [M-C ₁₅ H ₂₉ O] ⁺ (100%), 57 [M-C ₁₆ H ₃₁ O] ⁺ (33.3%), 43 [M-C ₁₇ H ₃₃ O] ⁺ (29.0%)
1		

47	4,8,12,16-tetramethyl	324 [M ⁺] (0.3%), 225 [M-C ₅ H ₇ O] ⁺ (0.3%), 197 [M-C ₇ H ₁₁ O ₂] ⁺ (0.7%), 155 [M-C ₁₀ H ₁₇ O ₂] ⁺ (2.3%),
	heptadecan-1,4-olide	$127 \ [M-C_{12}H_{21}O_2]^+ \ (6.7\%), \ 113 \ [M-C_5H_7O]^+ \ (3.3\%), \ 99 \ (100\%), \ 85 \ [M-C_{15}H_{27}O_2]^+ \ (16.0\%), \ 57 \ [M-C_{12}H_{21}O_2]^+ \ (16.0\%),$
		$C_{17}H_{31}O_2]^+$ (30.0%)
48	2-[4-methyl-6-(2,6,6-	324 [M ⁺] (0.2%), 274 (3.2%), 243 (2.3%), 217 (6.1%), 192 (3.2%), 165 (6.8%), 147 (33.9%), 133
	trimethylcyclohex-1-	(9.1%), 119 (18.5%), 105 (31.6%), 91 (100%), 69 (17.4%), 55 (24.8%)
	enyl)hexa-1,3,5-	
	trienyl]cyclohex-1-en-1-	
	carboxaldehyde	
49	gibberlline A3	346 [M ⁺] (1.0%), 327 (8.0%), 300 (2.0%), 281 (46.7%), 253 (13.3%), 207 (100%), 177 (4.0%), 159
		(6.7%), 96 (10.0%), 73 (18.3%), 55 (11.0%)
50	Squalene	410 [M ⁺] (0.7%), 367 [M-C ₃ H ₇] (0.3%), 341 [M-C ₅ H ₉] (2.7%), 281 (3.3%), 207 [M-C ₁₅ H ₂₅] (6.7%),
		191 [M-C ₁₆ H ₂₇] (3.3%), 137 [M-C ₂₀ H ₃₃] (16.3%), 123 [M-C ₂₁ H ₃₅] (10.0%), 69 [M-C ₂₅ H ₄₁] (100%),
		55 [M-C ₂₆ H ₄₃] (2.3%)
51	vitamin E	$430 \ [M^+] \ (71.0\%), \ 405 \ [M-C_2H_6]^+ \ (0.3\%), \ 355 \ (0.7\%), \ 327 \ \ (0.3\%), \ 281 \ [M-C_{10}H_{12}O]^+ \ (6.3\%), \ 252 \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ 327 \ \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5\%), \ (0.5$
		$[M-C_{11}H_{14}O_2]^+ (0.3\%), 225 [M-C_{13}H_{17}O_2]^+ (0.3\%), 205 [C_{13}H_{17}O_2]^+ (10.0\%), 191 (6.7\%), 165$
		$[C_{10}H_{13}O_2]^+$ (100%), 135 (6.7%), 71 $[M-C_{24}H_{39}O_2]^+$ (3.0%), 57 $[M-C_{25}H_{41}O_2]^+$ (6.7%)
52	3,4,3',4'tetrahydrospirillox	600 [M ⁺] (1.8%), 582 (5.3%), 569 [M-CH ₃ O] ⁺ (2.2%), 499 [M-C ₆ H ₁₃ O] ⁺ (2.2%), 470 [M-C ₈ H ₁₈ O] ⁺
	anthin	$(6.8\%), 459 [M-C_9H_{17}O]^+ (6.3\%) 429 (43.3\%), 352 [M-C_{17}H_{28}O]^+ (11.5\%), 340 [M-C_{19}H_{30}O]^+$
		(33.9%), 326 (27.1%), 282 (16.2%), 259 (27.1%), 241 (20.3%), 215 (49.2%), 193 (33.3%), 169 [M-
		C ₃₁ H ₄₃ O] ⁺ (29.3%), 121 (61.0%), 115 [M-C ₃₅ H ₄₉ O] ⁺ (42.7%), 105 (38.3%), 69 (100%)
53	1-methyl-9H-fluorine	180 [M ⁺] (70.0%), 165 [M-CH ₃] ⁺ (100%), 152 [M-C ₂ H ₄] ⁺ (15.7%), 141 (7.3%), 128 (10.0%), 111
		(10.0%), 97 (26.0%), 83 (20.0%), 69 (20.0%), 57 (23.3%)
54	Dioctyladipate	$341 [M^+] (4.5\%), 283 (2.5\%), 241 [M-C_8H_{17}O]^+ (18.1\%), 199 [M-C_{10}H_{19}O_2]^+ (9.7\%), 167 (5.6\%),$
		147 (40.6%), 129 $[M-C_{14}H_{25}O_3]^+$ (100%), 113 $[M-C_{14}H_{25}O_4]^+$ (2.2%), 83 (32.5), 71 $[M-C_{10}H_{19}O_2]^+$
		$(36.1\%), 57 [M-C_{17}H_{31}O_4]^+ (56,4\%)$

3.4.2 Antioxidant activity assessment

3.4.2.1 Free radical scavenging method (ABTS)

For each of the investigated fractions (2 µl) of ABTS solution was added to 3 μ l MnO₂ solution (25 mg/ μ l), all were prepared in (5 µl) aqueous phosphate buffer solution (pH 7, 0.1 M). The mixture was shaken, centrifuged, filtered and the absorbance of the resulting green blue solution (ABTS radical solution) at 734 nm was adjusted to approx. ca. 0.5. Then, 50 µl of (2 µM) solution of the tested fraction and the isolated compound in spectroscopic grade MeOH / phosphate buffer (1:1) was added. The absorbance was measured and the reduction in color intensity was expressed as inhibition percentage. L-ascorbic acid was used as standard antioxidant (positive control). Blank sample was run without ABTS and using MeOH / phosphate buffer (1:1) instead of tested fractions. Negative control was run with ABTS and MeOH / phosphate buffer (1:1) only.

3.4.3 Cytotoxicity assay

The cell lines MCF-7, HePG-2 and PC3 were used to determine the inhibitory effects of extracts on cell growth using the MTT assay (Mosmann and Immunol, 1983; Denizot et al., 1986). This colorimetric assay is based on the conversion of the yellow tetrazolium bromide (MTT) to a purple formazan derivative by mitochondrial succinate dehydrogenase in viable cells. Cell lines were cultured in RPMI-1640 medium with 10% fetal bovine serum. Antibiotics added were 100 units / µl penicillin and 100 µg/µl streptomycin at 37°C in a 5% CO2 incubator. The cell lines were seeded in a 96-well plate at a density of a 1.0x10⁴ cells/well at 37 °C for 48 h under 5% CO2. After incubation the cells were treated with different concentration of the fractions and isolated compound and incubated for 24 h. After 24 h of the treatment, 20 µl of MTT solution at 5 mg/µl was added and incubated for 4 h. Dimethyl sulfoxide (DMSO) in volume of 100µl is added into each well to dissolve the purple formazan formed. The colorimetric assay is measured and recorded at absorbance of 570 nm using a plate reader (EXL 800). The relative cell viability was calculated from the formula:

% Relative cell viability

- $\frac{\text{Absorbance 570 of treated samples}}{\text{Absorbance 570 of untreated sample}} x \ 100$

4. REFERENCES

- [1] Angiosperm Phylogeny Website. Retrieved 15 July 2014.
- [2] Fryxell P. A. 1997a. The American genera of MalvaceaeII. Brittonia. 49: 204-269.
- [3] Al-Gohary H. 2008. Floristic Composition of Eleven Wadis in Gebel Elba, Egypt. IJAB. 10: 151-160.
- [4] Shaltout K, Sheded G. M., and Salem A. 2010. Vegetation spatial heterogeneity in a hyper arid Biosphere Reserve area in North Africa. Acta Bot. Croat. 69: 31-46.

- [5] Alshamy M. M. 2016. Ecological study on wild vegetation of palm fields across some oases in western Desert, Egypt. CATRINA. 15: in press.
- [6] Qing ma shu. 2007. Flora of China. 12: 275-279.
- [7] Boulos L. 2002. Flora of Egypt. Al Hadara Publishing, Cairo, Egypt. 3: 229-231.
- [8] Vaghasiya Y., Chanda S., and Turk J. 2007. Biol. 31: 243-248.
- [9] Ali S., Yasmeen S., Afza N., Malik A., Iqbal L., Lateef M., Riaz N., and Ashraf M. J. 2009. Asian Nat Prod Res. 11: 457-464.
- [10] Eldahshan O. A. 2010. Isolation and Structure Elucidation of Phenolic Compounds of Carob Leaves Grown in Egypt. Curr. Res. J. Biol. Sci. 3: ISSN: 2041-0778.
- [11] Ibrahim A., Khalifa S., khafagi I., Youssef D., Khan S., Mesbah M. k., and Khan I. 2008. Microbial Metabolism of Biologically Active Secondary Metabolites from Nerium oleander L. Chem. Pharm. Bull. 56: 1256-1257.
- [12] Lissi E., Modak B., Torres R., Escobar J., and Urza A. 1999. Free Radical Res. 30: 471 – 477.
- [13] El-Gazar A. B. A., Youssef A. M. S., Youssef M. M., Abu-Hashem A. A., Badria F. A., and Eur. J. 2009. Med. Chem. 44: 609 – 624.
- [14] Aeschlach R., Loliger J., Scott C. B., Murcia A., Butler J., Halliwell B., and Aruoma I. O. 1994. Food Chem. Toxicol. 32: 31 – 36.
- [15] Stylianakis A., Kolocouris N., Kolocouris G., Fytas G. B., Foscolos E., Padalko J., Neyts D., and Clerq E. 2003. Bioorg, Med. Chem. Lett. 13: 1699 – 1703.
- [16] Mosmann T., and Immunol J. 1983. Methods. 65: 55-63.
- [17] Denizot F., Lang R., and Immunol J. 1986. Methods. 22: 271-277.
- [18] Mauceri H. J., Hanna N. N., Beckett M. A., Gorski D. H., Staba M. J., Stellato K. A., Bigelow K., Heimann R, Gately S., Dhanabal M., Soff G. A., Sukhatme V. P., Kufe D. W., and Weichselbaum R. R. 1998. Combined effects of agiostatin and ionizing radiation in antitumour therapy. Nature. 394: 287-291.